Top

Published in:

Open Access 01-12-2008 | Review Paper

Metastasis Suppressors and the Tumor Microenvironment

Authors: Thomas M. Bodenstine, Danny R. Welch

Published in: Cancer Microenvironment | Issue 1/2008

Abstract

The most dangerous attribute of cancer cells is their ability to metastasize. Throughout the process of metastasis, tumor cells interact with other tumor cells, host cells and extracellular molecules. This brief review explores how a new class of molecules – metastasis suppressors – regulate tumor cell–microenvironmental interactions. Data are presented which demonstrate that metastasis suppressors act at multiple steps of the metastatic cascade. A brief discussion for how metastasis suppressor regulation of cellular interactions might be exploited is presented.

Wolf K, Wu YI, Liu Y et al (2007) Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nat Cell Biol 9:893–904PubMed

Friedl P, Wolf K (2003) Tumour-cell invasion and migration: Diversity and escape mechanisms. Nat Rev Cancer 3:362–374PubMed

Weiss L, Orr FW, Honn KW (1989) Interactions between cancer cells and the microvasculature: A rate regulator for metastasis. Clin Exp Metastasis 7:127–167PubMed

Weiss L (1990) Metastatic inefficiencyAdv Cancer Res. 54:159–211PubMedCrossRef

Rennebeck G, Martelli M, Kyprianou N (2005) Anoikis and survival connections in the tumor microenvironment: Is there a role in prostate cancer metastasis? Cancer Res 65:11230–11235PubMed

Wang SL, El-Deiry WS (2003) TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 22:8628–8633PubMed

Fidler IJ (1974) Immune stimulation-inhibition of experimental cancer metastasis. Cancer Res 34:491–498PubMed

Hehlgans S, Haase M, Cordes N (2007) Signalling via integrins: Implications for cell survival and anticancer strategies. Biochim Biophys Acta Rev Cancer 1775:163–180

Cavallaro U, Christofori G (2001) Cell adhesion in tumor invasion and metastasis: loss of the glue is not enough. Biochim Biophys Acta Rev Cancer 1552:39–45

10.

Pauli BU, Augustin-Voss HG, El-Sabban ME et al (1990) Organ-preference of metastasis. The role of endothelial cell adhesion molecules. Cancer Metastasis Rev 9:175–189PubMed

11.

Nicolson GL (1988) Organ specificity of tumor metastasis: role of preferential adhesion, invasion and growth of malignant cells at specific secondary sites. Cancer Metastasis Rev 7:143–188PubMed

12.

Hart IR (1982) “Seed and soil” revisited: mechanisms of site-specific metastasis. Cancer Metastasis Rev 1:5–16PubMed

13.

Ruffini PA, Morandi P, Cabioglu N et al (2007) Manipulating the chemokine–chemokine receptor network to treat cancer. Cancer 109:2392–2404PubMed

14.

Naumov GN, MacDonald IC, Chambers AF et al (2001) Solitary cancer cells as a possible source of tumour dormancy? Semin Cancer Biol 11:271–276PubMed

15.

Al Mehdi AB, Tozawa K, Fisher AB et al (2000) Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nat Med 6:100–102PubMed

16.

Townson JL, Chambers AF (2006) Dormancy of solitary metastatic cells. Cell Cycle 5:1744–1750PubMed

17.

Chambers AF, Groom AC, MacDonald IC (2002) Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2:563–572PubMed

18.

Eccles SA, Welch DR (2007) Metastasis: recent discoveries and novel treatment strategies. Lancet 369:1742–1757PubMed

19.

Welch DR (2007) Do we need to redefine a cancer metastasis and staging definitions? Breast Disease 26:3–12

20.

Chambers AF, Matrisian LM (1997) Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89:1260–1270PubMed

21.

Vaidya KS, Welch DR (2007) Metastasis suppressors and their roles in breast carcinoma. J Mamm Gland Biol Neopl 12:175–190

22.

Rinker-Schaeffer CW, O’Keefe JP, Welch DR et al (2006) Metastasis suppressor proteins: Discovery, Molecular mechanisms and Clinical Application. Clin Cancer Res 12:3382–3389

23.

Guarino M, Rubino B, Ballabio G (2007) The role of epithelial–mesenchymal transition in cancer pathology. Pathology 39:305–318PubMed

24.

Graff JR, Gabrielson E, Fujii H et al (2000) Methylation patterns of the E-cadherin 5′ CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J Biol Chem 275:2727–2732PubMed

25.

Graff JR, Greenberg VE, Herman JG et al (1998) Distinct patterns of E-cadherin CpG island methylation in papillary, follicular, Hurthle’s cell, and poorly differentiated human thyroid carcinoma. Cancer Res 58:2063–2066PubMed

26.

Hugo H, Ackland ML, Blick T et al (2007) Epithelial–mesenchymal and mesenchymal–epithelial transitions in carcinoma progression. J Cell Physiol 213:374–383PubMed

27.

Potter JD (2007) Morphogens, morphostats, microarchitecture and malignancy. Nat Rev Cancer 7:464–474PubMed

28.

Hay ED (2005) The mesenchymal cell, its role in the embryo, and the remarkable signaling mechanisms that create it. Dev Dyn 233:706–720PubMed

29.

Thiery JP (2002) Epithelial–mesenchymal transitions in tumour progression. Nat Rev Cancer 2:442–454PubMed

30.

Foty RA, Steinberg MS(2004) Cadherin-mediated cell–cell adhesion and tissue segregation in relation to malignancy. Int J Dev Biol 48:397–409PubMed

31.

Kashima T, Nakamura K, Kawaguchi J et al (2003) Overexpression of cadherins suppresses pulmonary metastasis of osteosarcoma in vivo. Int J Cancer 104:147–154PubMed

32.

Puisieux A, Valsesia-Wittmann S, Ansieau S (2006) A twist for survival and cancer progression. Br J Cancer 94:13–17PubMed

33.

Yang J, Mani SA, Weinberg RA (2006) Exploring a new twist on tumor metastasis. Cancer Res 66:4549–4552PubMed

34.

Weaver AM (2006) Invadopodia: specialized cell structures for cancer invasion. Clin Exp Metastasis 23:97–105PubMed

35.

Christiansen JJ, Rajasekaran AK (2006) Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res 66:8319–8326PubMed

36.

Tarin D (2005) The fallacy of epithelial mesenchymal transition in neoplasia Cancer Res 65: 5996–6000PubMed

37.

Tarin D (2005) Carcinoma invasion and metastasis: A role for epithelial–mesenchymal transition? Response. Cancer Res 65:5995–5995

38.

Lin X, Tombler E, Nelson PJ et al (1996) A novel src- and ras-suppressed protein kinase C substrate associated with cytoskeletal architecture. J Biol Chem 271:28430–28438PubMed

39.

Gelman IH, Lee K, Tombler E et al (1998) Control of cytoskeletal architecture by the src-suppressed C kinase substrate, SSeCKS. Cell Motil Cytoskelet 41:1–17

40.

Xia W, Unger P, Miller L et al (2001) The Src-suppressed C kinase substrate, SSeCKS, is a potential metastasis inhibitor in prostate cancer. Cancer Res 61:5644–5651PubMed

41.

Lin X, Nelson P, Gelman IH (2000) SSeCKS, a major protein kinase C substrate with tumor suppressor activity, regulates G(1)–>S progression by controlling the expression and cellular compartmentalization of cyclin D. Mol Cell Biol 20:7259–7272PubMed

42.

Xia W, Gelman IH (2002) Mitogen-induced, FAK-dependent tyrosine phosphorylation of the SSeCKS scaffolding protein. Exp Cell Res 277:139–151PubMed

43.

Steeg PS, Bevilacqua G, Kopper L et al (1988) Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst 80:200–204PubMed

44.

Pozzatti R, Muschel RJ, Williams J et al (1986) Primary rat embryo cells transformed by one or two oncogenes show different metastatic potentials. Science 232:223–227PubMed

45.

Hartsough MT, Steeg PS (2000) Nm23/nucleoside diphosphate kinase in human cancers. J Bioenerg Biomembranes 32:301–308

46.

Freije JM, MacDonald NJ, Steeg PS (1998) Nm23 and tumour metastasis: basic and translational advances. Biochem Soc Symp 63:261–271PubMed

47.

McDermott WG, Boissan M, Lacombe ML et al (2007) Nm23-H1 homologs suppress tumor cell motility and anchorage independent growth. Clin Exp Metastasis. doi:10.1007/s10585-007-9128-0

48.

Hailat N, Keim DR, Melhem RF et al (1991) High levels of p19/nm23 protein in neuroblastoma are associated with advanced stage disease and with N-myc gene amplification. J Clin Invest 88:341–345PubMed

49.

Fournier HN, Dupé-Manet S, Bouvard D et al (2002) Integrin cytoplasmic domain-associated protein 1α (ICAP-1α) interacts directly with the metastasis suppressor nm23-H2, and both proteins are targeted to newly formed cell adhesion sites upon integrin engagement. J Biol Chem 277:20895–20902PubMed

50.

Tee YT, Chen GD, Lin LY et al (2006) Nm23-H1: a metastasis-associated gene. Taiwan J Obstet Gynecol 45:107–113PubMed

51.

Otsuki Y, Tanaka M, Yoshii S et al (2001) Tumor metastasis suppressor nm23H1 regulates Rac1 GTPase by interaction with Tiam1. Proc Natl Acad Sci 98:4385–4390PubMed

52.

Kuppers DA, Lan K, Knight JS et al (2005) Regulation of matrix metalloproteinase 9 expression by Epstein-Barr virus nuclear antigen 3C and the suppressor of metastasis Nm23-H1. J Virol 79:9714–9724PubMed

53.

Che G, Chen J, Liu L et al (2006) Transfection of nm23-H1 increased expression of beta-Catenin, E-Cadherin and TIMP-1 and decreased the expression of MMP-2, CD44v6 and VEGF and inhibited the metastatic potential of human non-small cell lung cancer cell line L9981. Neoplasma 53:530–537PubMed

54.

Horak CE, Lee JH, Elkahloun AG et al (2007) Nm23-H1 suppresses tumor cell motility by down-regulating the lysophosphatidic acid receptor EDG2. Cancer Res 67:7238–7246PubMed

55.

Kishi J, Tanaka R, Koiwai O et al (1994) Gelatinases and metalloproteinase inhibitor secreted by murine colonic carcinoma cells with differing metastatic potential. Cell Biol Int 18:165–170PubMed

56.

Li H, Fang W, Shi Z (1997) Effects of TIMP-2 gene transfection on biological behaviors of a metastatic human lung carcinoma cell line. Zhonghua Yi Xue Za Zhi 77:652–656PubMed

57.

Lopez-Otin C, Matrisian LM (2007) Emerging roles of proteases in tumour suppression. Nat Rev Cancer 7:800–808PubMed

58.

Takahashi C, Sheng Z, Horan TP et al (1998) Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proc Natl Acad Sci 95:13221–13226PubMed

59.

Noda M, Oh J, Takahashi R et al (2003) RECK: a novel suppressor of malignancy linking oncogenic signaling to extracellular matrix remodeling. Cancer Metastasis Rev 22:167–175PubMed

60.

Correa TCS, Brohem CA, Winnischofer SMB et al (2006) Downregulation of the RECK-tumor and metastasis suppressor gene in glioma invasiveness. J Cell Biochem 99:156–167PubMed

61.

Span PN, Sweep CGJF, Manders P et al (2003) Matrix metalloproteinase inhibitor reversion-inducing cysteine-rich protein with Kazal motifs – A prognostic marker for good clinical outcome in human breast carcinoma. Cancer 97:2710–2715PubMed

62.

Oh J, Seo DW, Diaz T et al (2004) Tissue inhibitors of metalloproteinase 2 inhibits endothelial cell migration through increased expression of RECK. Cancer Res 64:9062–9069PubMed

63.

Noda M, Takahashi C (2007) Recklessness as a hallmark of aggressive cancer. Cancer Sci 98:1659–1665PubMed

64.

Chang HC, Cho CY, Hung WC (2006) Silencing of the metastasis suppressor RECK by RAS oncogene is mediated by DNA methyltransferase 3b-induced promoter methylation. Cancer Res 66:8413–8420PubMed

65.

Chang HC, Liu LT, Hung WC (2004) Involvement of histone deacetylation in ras-induced down-regulation of the metastasis suppressor RECK. Cell Signal 16:675–679PubMed

66.

Liu LT, Chang HC, Chiang LC et al (2003) Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. Cancer Res 63:3069–3072PubMed

67.

Oh J, Takahashi R, Kondo S et al (2001) The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 107:789–800PubMed

68.

Li SL, Gao DL, Zhao ZH et al (2007) Correlation of matrix metalloproteinase suppressor genes RECK, VEGF, and CD105 with angiogenesis and biological behavior in esophageal squamous cell carcinoma. World J Gastroenterol 13:6076–6081PubMed

69.

Dong JT, Lamb PW, Rinker-Schaeffer CW et al (1995) KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 268:884–886PubMed

70.

Liu WM, Zhang XA (2006) KAI1/CD82, a tumor metastasis suppressor. Cancer Lett 240:183–194PubMed

71.

Kauffman EC, Robinson VL, Stadler WM et al (2003) Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site. J Urol 169:1122–1133PubMed

72.

Jee BK, Park KM, Surendran S et al (2006) KAI1/CD82 suppresses tumor invasion by MMP9 inactivation via TIMP1 up-regulation in the H1299 human lung carcinoma cell line. Biochem Biophys Res Commun 342:655–661PubMed

73.

Bandyopadhyay S, Zhan R, Chaudhuri A et al (2006) Interaction of KAI1 on tumor cells with DARC on vascular endothelium leads to metastasis suppression. Nat Med 12:933–938PubMed

74.

Seraj MJ, Samant RS, Verderame MF et al (2000) Functional evidence for a novel human breast carcinoma metastasis suppressor, BRMS1, encoded at chromosome 11q13. Cancer Res 60:2764–2769PubMed

75.

Shevde LA, Samant RS, Goldberg SF et al (2002) Suppression of human melanoma metastasis by the metastasis suppressor gene, BRMS1. Exp Cell Res 273:229–239PubMed

76.

Zhang S, Lin QD, DI W (2006) Suppression of human ovarian carcinoma metastasis by the metastasis-suppressor gene, BRMS1. Int J Gynecol Cancer 16:522–531PubMed

77.

Lombardi G, Di Cristofano C, Capodanno A et al (2006) High level of messenger RNA for BRMS1 in primary breast carcinomas is associated with poor prognosis. Int J Cancer 120:1169–1178

78.

Zhang Z, Yamashita H, Toyama T et al (2006) Reduced expression of the breast cancer metastasis suppressor 1 mRNA is correlated with poor progress in breast cancer. Clin Cancer Res 12:6410–6414PubMed

79.

Ohta S, Lai EW, Pang ALY et al (2005) Downregulation of metastasis suppressor genes in malignant pheochromocytoma. Int J Cancer 114:139–143PubMed

80.

Stark AM, Tongers K, Maass N et al (2004) Reduced metastasis-suppressor gene mRNA-expression in breast cancer brain metastases. J Cancer Res Clin Oncol 131:191–198PubMed

81.

Kelly LM, Buggy Y, Hill A et al (2005) Expression of the breast cancer metastasis suppressor gene, BRMS1, in human breast carcinoma: lack of correlation with metastasis to axillary lymph nodes. Tumor Biol 26:213–216

82.

Hicks DG, Yoder BJ, Short S et al (2006) Loss of BRMS1 protein expression predicts reduced disease-free survival in hormone receptor negative and HER2 positive subsets of breast cancer. Clin Cancer Res 12:6702–6708PubMed

83.

Hurst DR, Mehta A, Moore BP et al (2006) Breast cancer metastasis suppressor 1 (BRMS1) is stabilized by the Hsp90 chaperone. Biochem Biophys Res Commun 348:1429–1435PubMed

84.

Meehan WJ, Samant RS, Hopper JE et al (2004) Breast cancer metastasis suppressor 1 (BRMS1) forms complexes with retinoblastoma-binding protein 1 (RBP1) and the mSin3 histone deacetylase complex and represses transcription. J Biol Chem 279:1562–1569PubMed

85.

Champine PJ, Michaelson J, Weimer B et al (2007) Microarray analysis reveals potential mechanisms of BRMS1-mediated metastasis suppression. Clin Exp Metastasis 24:551–565PubMed

86.

Liu Y, Smith PW, Jones DR (2006) Breast cancer metastasis suppressor 1 functions as a corepressor by enhancing histone deacetylase 1-mediated deacetylation of RelA/p65 and promoting apoptosis. Mol Cell Biol 26:8683–8696PubMed

87.

Phadke PA, Vaidya KS, Nash KT et al (2008) BRMS1 suppresses breast cancer experimental metastasis to multiple organs by inhibiting several steps of the metastatic process. Am J Pathol (in press)

88.

Simon AM (1999) Gap junctions: more roles and new structural data. Trends Cell Biol 9:169–170PubMed

89.

Samant RS, Seraj MJ, Saunders MM et al (2001) Analysis of mechanisms underlying BRMS1 suppression of metastasis. Clin Exp Metastasis 18:683–693

90.

Saunders MM, Seraj MJ, Li ZY et al (2001) Breast cancer metastatic potential correlates with a breakdown in homospecific and heterospecific gap junctional intercellular communication. Cancer Res 61:1765–1767PubMed

91.

Kapoor P, Saunders MM, Li Z et al (2004) Breast cancer metastatic potential: Correlation with increased heterotypic gap junctional intercellular communication between breast cancer cells and osteoblastic cells. Int J Cancer 111:693–697PubMed

92.

Rinker-Schaeffer CW, Hawkins AL, Ru N et al (1994) Differential suppression of mammary and prostate cancer metastasis by human chromosomes 17 and 11. Cancer Res 54:6249–6256PubMed

93.

Chekmareva MA, Hollowell CP, Smith RC et al (1997) Localization of prostate cancer metastasis-suppressor activity on human chromosome 17. Prostate 33:271–280PubMed

94.

Yoshida BA, Dubauskas Z, Chekmareva MA et al (1999) Identification and characterization of candidate prostate cancer metastasis-suppressor genes encoded on human chromosome 17. Cancer Res 59:5483–5487PubMed

95.

Yoshida BA, Dubauskas Z, Chekmareva MA et al (1999) Mitogen-activated protein kinase kinase 4/stress-activated protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17. Cancer Res 59:5483–5487PubMed

96.

Kim HL, Van der Griend DJ, Yang X et al (2001) Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers. Cancer Res 61:2833–2837PubMed

97.

Yamada SD, Hickson JA, Hrobowski Y et al (2002) Mitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma. Cancer Res 62:6717–6723PubMed

98.

Hickson JA, Huo D, Vander Griend DJ et al (2006) The p38 Kinases MKK4 and MKK6 suppress metastatic colonization in human ovarian carcinoma. Cancer Res 66:2264–2270PubMed

99.

Vander Griend DJ, Kocherginsky M, Hickson JA et al (2005) Suppression of metastatic colonization by the context-dependent activation of the c-jun NH2-terminal kinase kinases JNKK1/MKK4 and MKK7. Cancer Res 65:10984–10991PubMed

100.

Vander Griend DJ, Rinker-Schaeffer CW (2004) A new look at an old problem: the survival and organ-specific growth of metastases. Sci STKE 2004:216pe3PubMed

101.

Aguirre-Ghiso JA (2006) The problem of cancer dormancy – understanding the basic mechanisms and identifying therapeutic opportunities. Cell Cycle 5:1740–1743PubMed

102.

Aguirre-Ghiso JA, Estrada Y, Liu D et al (2003) ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res 63:1684–1695PubMed

103.

Lee J-H, Miele ME, Hicks DJ et al (1996) KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. J Natl Cancer Inst 88:1731–1737PubMed

104.

Nash KT, Welch DR (2006) The KISS1 metastasis suppressor: mechanistic insights and clinical utility. Front Biosci 11:647–659PubMed

105.

Nash KT, Phadke PA, Navenot J-M et al (2007) KISS1 metastasis suppressor secretion, multiple organ metastasis suppression, and maintenance of tumor dormancy. J Natl Cancer Inst 99:309–321PubMed

106.

Kotani M, Detheux M, Vandenbogaerde A et al (2001) The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54. J Biol Chem 276:34631–34636PubMed

107.

Muir AI, Chamberlain L, Elshourbagy NA et al (2001) AXOR12: A novel human G protein-coupled receptor, activated by the peptide KiSS-1. J Biol Chem 276:28969–28975PubMed

108.

Ohtaki T, Shintani Y, Honda S et al (2001) Metastasis suppressor gene KiSS1 encodes peptide ligand of a G-protein-coupled receptor. Nature 411:613–617PubMed

Title: Metastasis Suppressors and the Tumor Microenvironment
Authors: Thomas M. Bodenstine
Danny R. Welch
Publication date: 01-12-2008
Publisher: Springer Netherlands
Published in: Cancer Microenvironment / Issue 1/2008
Print ISSN: 1875-2292
Electronic ISSN: 1875-2284
DOI: https://doi.org/10.1007/s12307-008-0001-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2008

Emerging Roles of PAR-1 and PAFR in Melanoma Metastasis

Systems Biology: A Therapeutic Target for Tumor Therapy

A Dialogue between the Hypoxia-Inducible Factor and the Tumor Microenvironment

The Epigenetic Influence of Tumor and Embryonic Microenvironments: How Different are They?

The Prometastatic Microenvironment of the Liver

Microenvironment Changes (in pH) Affect VEGF Alternative Splicing

Keynote webinar | Spotlight on antibody–drug conjugates in cancer